Flumatinib, CAS 895519-90-1

Formulation: A solid

Formal Name: 4-[(4-methyl-1-piperazinyl)methyl]-N-[6-methyl-5-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-3-pyridinyl]-3-(trifluoromethyl)-benzamide

Purity: ≥98%

Formula Markup: C29H29F3N8O

Formula Weight: 562,6

Shelf life (days): 1460

CAS Number: 895519-90-1

Notes: Flumatinib is an inhibitor of the non-receptor tyrosine kinase Bcr-Abl (IC50 = 1.2 nM).{62915} It is selective for Bcr-Abl over VEGFR2, c-Src, EGFR, and HER2 at 1 µM but does inhibit PDGFRβ and c-Kit (IC50s = 307.6 and 665.5 nM, respectively). Flumatinib inhibits the proliferation of K562 chronic myelogenous leukemia (CML) cells expressing wild-type Bcr-Abl (IC50 = 5.1 nM) and 32D cells expressing the Bcr-Abl mutations Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblE255K, Bcr-AblM351T, and Bcr-AblH396P (IC50s = 76.3, 40.4, 123.2, 20.2, and 34.6 nM, respectively), which confer resistance to the c-Abl, Bcr-Abl, PDGFR, and c-Kit inhibitor imatinib (Item No. 13139). It also induces tumor regression and increases survival time in a K562 mouse xenograft model when administered at a dose of 75 mg/kg per day. Flumatinib also increases the viability of Vero E6 cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; EC50 = 1.6 µM) and reduces the levels of SARS-CoV-2 in the supernatant of Vero E6 infected cells.{62916}

• Artikelnummer: CAY36226-10
• Hersteller: Cayman Chemical
• Hersteller Artikelnummer: 36226-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK
• Methode: Reinstoffe